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Abstract
Introduction Existing methods to detect breast cancer in
asymptomatic patients have limitations, and there is a need to
develop more accurate and convenient methods. In this study,
we investigated whether early detection of breast cancer is
possible by analyzing gene-expression patterns in peripheral
blood cells.
Methods Using macroarrays and nearest-shrunken-centroid
method, we analyzed the expression pattern of 1,368 genes in
peripheral blood cells of 24 women with breast cancer and 32
women with no signs of this disease. The results were validated
using a standard leave-one-out cross-validation approach.
Results We identified a set of 37 genes that correctly predicted
the diagnostic class in at least 82% of the samples. The majority
of these genes had a decreased expression in samples from
breast cancer patients, and predominantly encoded proteins
implicated in ribosome production and translation control. In
contrast, the expression of some defense-related genes was
increased in samples from breast cancer patients.
Conclusion The results show that a blood-based gene-
expression test can be developed to detect breast cancer early
in asymptomatic patients. Additional studies with a large sample
size, from women both with and without the disease, are
warranted to confirm or refute this finding.
Introduction
Early detection of breast cancer can improve the chances of
successful treatment and recovery. To date, mammographic
screening is the most reliable method to detect breast cancer
in asymptomatic patients. Although highly effective, it has sig-
nificant limitations, so that the development of more accurate,
convenient, and objective detection methods is needed. In the
absence of microcalcification, mammography often fails to
detect tumors that are less than 5 mm in size, and also mam-
mograms of women with dense breast tissue are difficult to
interpret. For example, in a study of over 11,000 women with
no clinical symptoms of breast cancer, the sensitivity of mam-
mography was only 48% for the subset of women with
extremely dense breasts, compared with 78% sensitivity for
the entire sample of women in the study [1]. In addition, when
an abnormality has been detected, further tests involving inva-
sive steps must complement mammography to establish
whether the detected abnormality is a cancer.
ANOVA = analysis of variance; EDTA = ethylenediaminetetraacetic acid; eEF = eukaryotic elongation factor; RACK1 = receptor for activated C kinase 
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A vast amount of literature is already available describing the
potential use of large-scale gene expression analysis in dis-
ease diagnosis, including breast cancer [2-8]. However, most
published work with implications in cancer diagnosis has
involved clinical samples comprising either diseased tissues or
cells. Obtaining such samples for clinical purposes requires a
prior knowledge of both their presence and their location in the
body. A gene-expression-based test to detect cancers that
does not rely upon the availability of tissues or cells from the
diseased area has not yet been described.
It has recently been suggested that circulating leukocytes can
be viewed as scouts, continuously maintaining a vigilant and
comprehensive surveillance of the body for signs of infection
or other threats, including cancer [9]. In line with this view, we
show that peripheral blood can be used to develop a gene-
expression-based test for early detection of breast cancer. The
rationale for using blood cells as monitors for a malignant dis-
ease elsewhere in the body is based on the hypothesis that a
malignant growth will cause characteristic changes in the bio-
chemical environment of blood. These changes will affect the
expression pattern of certain genes in blood cells.
In this pilot study, we have analyzed gene-expression patterns
in peripheral blood cells of women diagnosed with breast can-
cer and women with no signs of this disease. We have identi-
fied a panel of genes with distinct expression patterns in
cancer versus noncancer samples. The results indicate that
breast cancer causes characteristic changes in the biochemi-
cal environment of blood already during early stages of dis-
ease development. Blood cells sense and respond to the
change by decreasing the expression of genes involved in pro-
tein synthesis and increasing the expression of defense-
related genes. We show that the expression pattern of the
identified genes can be used to discriminate and predict the
class of breast cancer and non-breast-cancer samples with
high accuracy. Our findings should pave way for the develop-
ment of a blood-based gene-expression test for early detec-
tion of breast cancer.
Materials and methods
Blood samples
Blood samples were collected from donors with their informed
consent under an approval from Regional Ethical Committee
of Norway (331-99-99138). All donors were treated anony-
mously during analysis. Blood was drawn from women with a
suspect initial mammogram, prior to any knowledge of whether
the abnormality observed during first screening was benign or
malignant. In all cases, the blood samples were drawn
between 8 a.m. and 4 p.m. From each woman, 10 ml blood
was drawn by skilled personnel either in vacutainer tubes con-
taining ethylenediaminetetraacetic acid (EDTA) as anticoagu-
lant (Becton Dickinson, Baltimore, MD, USA) or directly in
PAXgene™ tubes (PreAnalytiX, Hombrechtikon, Switzerland).
Blood collected in EDTA-containing tubes was immediately
stored at -80°C, while PAX tubes were left overnight at room
temperature and then stored at -80°C until use.
Preparation of cDNA arrays
One thousand four hundred thirty-five cDNA clones were ran-
domly picked from a plasmid library constructed from whole
blood of 550 healthy individuals (Clontech, Palo Alto, CA,
USA). Based on the sequence analysis of more than 500
cDNAs, redundancy among the randomly picked clones was
estimated to be about 20%. For amplification of inserts, bac-
terial clones were grown in microtiter plates containing 150 µl
Luria Broth media with 50 µg/ml carbenicillin, and incubated
overnight with agitation at 37°C. To lyse the cells, 5 µl of each
culture was diluted with 50 µl dH2O and incubated for 12 min
at 95°C. Of this mixture, 2 µl were subjected to a PCR reaction
using 40 µmol of 5' – and 3' – sequencing primers in the pres-
ence of 1.5 mM MgCl2. PCR reactions were performed with
the following cycling protocol: 4 min at 95°C, followed by 25
cycles of 1 min at 94°C, 1 min at 60°C, and 3 min at 72°C
either in a RoboCycler Temperature Cycler (Stratagene, La
Jolla, CA, USA) or DNA Engine Dyad Peltier Thermal Cycler
(MJ Research Inc, Waltham, MA, USA). The amplified prod-
ucts were denatured with NaOH (0.2 M, final concentration)
for 30 min and spotted onto Hybond-N+ membranes (Amer-
sham Pharmacia Biotech, Little Chalfont, UK), using a Micro-
Grid II workstation in accordance with the manufacturer's
instructions (BioRobotics Ltd, Cambridge, UK). The immobi-
lized cDNAs were fixed using a UV cross-linker (Hoefer Scien-
tific Instruments, San Francisco, CA, USA).
The printed arrays also contained controls for assessing back-
ground level, consistency, and sensitivity of the assay. These
were spotted at multiple positions in addition to the 1,435
cDNAs, and included controls such as PCR mix (without any
insert); controls of the SpotReport™ 10-array validation sys-
tem (Stratagene), and cDNAs corresponding to constitutively
expressed genes such as β -actin, γ -actin, glyceraldehyde-3-
phosphate dehydrogenase, human ornithine decarboxylase
and cyclophilin.
RNA extraction, probe synthesis, and hybridization
Blood collected in EDTA tubes was thawed at 37°C and trans-
ferred to PAX tubes, and total RNA was purified in accordance
with the supplier's instructions (PreAnalytiX). From blood col-
lected directly in PAX tubes, total RNA was extracted in the
tubes as above without any transfer to new tubes. Contaminat-
ing DNA was removed from the isolated RNA by DNAase I
treatment using a DNA-free kit (Ambion Inc, Austin, TX, USA).
RNA quality was determined visually by inspecting the integrity
of 28S and 18S ribosomal bands after agarose-gel electro-
phoresis. Only samples from which good-quality RNA was
extracted were used in this study. In our experience, blood col-
lected in EDTA tubes often resulted in poor-quality RNA,
whereas blood collected in PAX tubes almost always yielded
good-quality RNA. The concentration and purity of extractedAvailable online http://breast-cancer-research.com/content/7/5/R634
R636
RNA were determined by measuring the absorbance at 260
nm and 280 nm. From the total RNA, mRNA was isolated
using Dynabeads in accordance with the supplier's instruc-
tions (Dynal AS, Oslo, Norway).
Labeling and hybridization experiments were performed in 16
batches. The number of samples assayed in each batch varied
from six to nine. To minimize the noise due to batch-to-batch
variation in printing, only the arrays manufactured during the
same print run were used in each batch. When samples were
assayed more than once (replicates), aliquots from the same
mRNA pool were used for probe synthesis. For probe synthe-
sis, aliquots of mRNA corresponding to 4 to 5 µg of total RNA
were mixed together with oligodT25NV (0.5 µg/µl) and mRNA
spikes of the SpotReport™ 10-array validation system (10 pg;
Spike 2, 1 pg), heated to 70°C, and then chilled on ice. The
probes were synthesized by reverse transcription in 35 µl
reaction mix in the presence of 50 µCi [α 33P]dATP, 3.5 µM
dATP, 0.6 mM each of dCTP, dTTP, dGTP, 200 units of
SuperScript II reverse transcriptase (Invitrogen, Life Technolo-
gies, Carlsbad, CA, USA), and 0.1 M DTT labeling for 1.5
hours at 42°C. After synthesis, the enzyme was deactivated for
10 min at 70°C and mRNA removed by incubating the reaction
mix for 20 min at 37°C in 4 units of Ribo H (Promega, Madison,
WI, USA). Unincorporated nucleotides were removed using
ProbeQuant G 50 columns (Amersham Biosciences, Piscata-
way, NJ, USA).
The membranes were equilibrated in 4 × standard saline cit-
rate (SSC) (1 × SSC, 0.15 M NaCl, 0.015 M sodium citrate,
pH 7.0) for 2 hours at 30°C and prehybridized overnight at
65°C in 10 ml prehybridization solution (4 × SSC, 0.1 M
NaH2PO4, 1 mM EDTA, 8% dextran sulfate, 10 × Denhardt's
solution, 1% SDS). Freshly prepared probes were added to 5
ml of the same prehybridization solution, and hybridization con-
tinued overnight at 65°C. The membranes were washed at
65°C with increasing stringency (2 × 30 min each in 2 × SSC,
0.1% SDS; 1 × SSC, 0.1% SDS; 0.1 × SSC, 0.1% SDS).
Quantification of hybridization signals
The hybridized membranes were exposed to Phosphoscreens
(super resolution) and an image file generated using Phos-
phoImager (Cyclone, Packard, Meriden, CT, USA). The identi-
fication and quantification of the hybridization signals, as well
as subtraction of local background values, were performed
using Phoretix™ software (Nonlinear Dynamics, Newcastle
upon Tyne, UK). For background subtraction, the median of
the line of pixels around each spot outline was subtracted from
the intensity of the signals assessed in each spot.
Data analysis
From the background-subtracted data for 1,435 genes,
1.25% of the lowest and 1.25% of the highest signals were
trimmed from each membrane. Since the cDNAs with signals
falling within this range varied between membranes, values of
67 cDNAs in total were removed from all membranes, and the
expression data for only 1,368 genes were further analyzed.
The data were normalized by dividing the value of each spot by
the mean of signals in each array followed by a cube-root
transformation. Supplementary Fig. 1 (left panel) (Additional
file 1) shows a clear batch effect in the cube-root-normalized
data (similar effects were also visible in the raw data). A simple
one-way analysis of variance (ANOVA) was performed to
adjust for the batch effects. Supplementary Fig. 1 (right panel)
(Additional file 1) shows that the systematic batch effects
were removed by the ANOVA adjustment. The batch-adjusted
data were then analyzed using the nearest-shrunken-centroid
method [10].
In this method, standard 'external' cross-validation is used to
determine the optimal shrinkage threshold. This optimal
threshold is then used with the full training set to construct the
centroid. As a result, for each value of the threshold, the esti-
mate of cross-validation error obtained is approximately unbi-
ased for the true test-error rate.
The leave-one-out cross-validation approach was used in this
work. The data were divided into M nonoverlapping subsets
(M = number of unique blood samples present). The model
was then trained M-1 times on these subsets combined, each
time leaving out one of the subsets (unique blood sample)
from the training data, but using only the omitted subset to
compute the prediction error. The errors obtained on all parts
were added together and used to compute the overall misclas-
sification error. It is well known that leave-one-out cross-valida-
tion provides an approximately unbiased and reliable estimate
of the misclassification rate that would be obtained from an
independent sample of patients [11,12]. In the terminology of
Ambroise and McLachlan [12], we used external cross-valida-
tion (as they recommend).
The raw and the batch-adjusted data for 1,368 genes in an
Excel file is provided in Supplementary Table 1 (Additional file
2) and Supplementary Table 2 (Additional file 3).
Results
We analyzed gene-expression patterns in 60 blood samples
obtained from 56 different women (Table 1). The experiments
were performed in 16 batches. To investigate the reproducibil-
ity of results, 13 samples from women with breast cancer and
23 samples from women with no breast cancer were analyzed
in different batches using aliquots from the same mRNA pool,
giving a total of 102 experimental samples.
The generated expression data was preprocessed and then
analyzed by the nearest-shrunken-centroid method [10]. A
standard leave-one-out cross-validation approach was used to
determine the optimal amount of shrinkage threshold. Since
we had 60 unique blood samples and for some of them exper-
iments were replicated more than once, for cross-validationBreast Cancer Research    Vol 7 No 5    Sharma et al.
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the data were divided into 60 nonoverlapping subsets, where
each subset represented a unique blood sample and included
all the replicates present in the data set. A sample was judged
as correctly classified only when a majority of members in the
corresponding cross-validation segment were correctly classi-
fied. The minimum overall misclassification error was observed
at a threshold value of 2.28, yielding a subset of 37 genes (Fig.
1). At this threshold, 10 of the 57 samples were misclassified
and 3 samples were judged nondecisions, because there was
no majority for either the breast-cancer or non-breast-cancer
class (Table 2). A detailed prediction result is presented in
Table 1.
The prediction was highly accurate for samples from women
with early stages of breast cancer, stage 0 and stage I. Among
the 14 samples representing early stages, there was one non-
decision and 11 of 13 samples were correctly predicted. Five
of seven stage II and one of two stage III samples were cor-
rectly predicted.
Most of the cancer samples (22 of 24) analyzed in this study
were obtained from women who had cancer of ductal origin.
One woman, the origin of whose cancer was not known, had
a previous history of breast cancer and at the time of blood col-
lection the cancer had spread to supraclavicular and infracla-
vicular nodes. Another sample that did not belong to the ductal
group was obtained from a woman who had invasive lobular
carcinoma in one breast and a tubular adenocarcinoma in the
other. Unlike ductal carcinoma, which originates from cells lin-
ing ducts, lobular carcinoma originates from cells lining lob-
ules. Both samples were incorrectly predicted. It is possible
that cancer of other than ductal origin affects the expression
pattern of the selected 37 genes in blood cells differently than
ductal carcinomas.
Seventeen of 19 samples obtained from women with a sus-
pect first mammogram were correctly predicted (Table 1, sub-
group A2), indicating the expression profile of the selected 37
genes to be highly efficient in discriminating between cancer-
ous and noncancerous breast abnormalities. In two samples,
we were not able to make any diagnostic decision.
Among the 17 samples from women with no reported breast
abnormality, 13 were correctly predicted (Table 1, subgroup
A3). These included samples from breast-feeding women as
well as those drawn at different times in the menstrual cycle
from one woman. However, the three samples from pregnant
women and a sample from a woman with acute bacterial infec-
tion at the time of blood collection were all incorrectly pre-
dicted. The woman with acute bacterial infection was, in
addition, chronically infected with Epstein–Barr virus. It is
known that both pregnancy and chronic infection may elicit
Figure 1
Misclassification rate as a function of threshold value and the number of genes involved Misclassification rate as a function of threshold value and the number of genes involved. The error was calculated using the majority rule. A nondeci-
sion was counted as an error. The upper graph shows that the minimum overall misclassification error was observed at a threshold value of 2.28. The 
lower graph shows the profile for misclassification error for breast-cancer (C) and non-breast-cancer (N) samples as a function of threshold value 
and the number of genes involved.Available online http://breast-cancer-research.com/content/7/5/R634
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Table 1
Gene-expression patterns in 60 blood samples obtained from 56 different women
Subgroup A1: Women with breast cancer
Sample ID Age (y) Stage Histology Grade Size (mm) Nodes Comments/ other 
disease if present
Times assayed Prediction 
(37 genes)
35 4 I I D C 1 1 1 0 # 2 +
56 7 0 D C I S 2 2 0 0 # 3 +
7 51 II IDC 3 20 1/7 # 2 +
8 84 II IDC 1 22 2/2 # 2 +
15 66 I IDC 2 15 0 Rheumatic disease 3 +
16 68 I IDC 1 7 0 # 1 +
17 66 II IDC 1 26 0 Epilepsy 1 -
27 48 I IDC 2 4 0 # 2 ND
31 47 I IDC 2 15 0 # 2 -
35 44 II IDC 2 25 0 # 1 +
36 50 I Multifocal IDC 1 5 × 14 0 # 1 -
38 n.a. 0 DCIS 2 9 0 # 1 +
39 65 I IDC 1 15 0 # 1 +
40 n.a. I IDC 2 14 0 Psoriasis 1 +
42 71 I IDC 1 8 0 # 1 +
44 55 III IDC 1 35 0 # 1 +
45 63 II IDC 3 23 0 # 1 -
48 65 IV - - - Metastases in supra- and 
infra- clavicular nodes
Breast cancer, 1982 1 -
49 65 I IDC 1 11 0 Type 2 diabetes 3 +
50 69 III ILC 2 50 2/19 # 2 -
51 50 II IDC 2 24 0 # 2 +
53 60 II IDC 2 23 0 # 2 +
59 63 I IDC 1 10 0 # 2 +
60 52 I IDC 1 3 0 # 2 +
Subgroup A2: Women with abnormal first mammography
Sample ID Age (y) Breast abnormality Comments / other 
disease if present
Times assayed Prediction 
(37 genes)
1 44 Benign density # 2 +
2 53 Benign microcalcifications Encapsulated cyst in 
left knee
2+
4 45 Benign density # 2 +
11 46 Benign density Ulcerative colitis 
since 1983
2+
12 44 Benign density # 2 +
13 50 Benign density Type 1 diabetes 2 +
14 47 Benign microcalcifications # 2 +
19 46 Benign density, cyst Crohn's disease 2 +
20 n.a. Benign density Rheumatic disease 1 +
28 44 Benign microcalcifications # 2 +
29 63 Benign density, cyst Fibromyalgia 2 ND
30 46 Benign density # 2 +Breast Cancer Research    Vol 7 No 5    Sharma et al.
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responses that can mimic breast cancer. During late preg-
nancy, similar to breast cancer, cells of mammary epithelial
buds divide to form ducts infiltrating breast stroma and build a
local blood supply. Also, both breast cancer and chronic infec-
tions are known to induce inflammatory responses in the body.
We also calculated the misclassification error, taking an aver-
age of the class probability for each sample in all 60 cross-val-
idation segments as compared with our previous approach in
which a sample was judged as correctly classified only when
a majority of members in the corresponding cross-validation
segment were correctly classified. Thus, each segment repre-
sented an average class probability for each sample, and we
predicted each sample to the class with the highest average
probability. The main purpose of adopting this approach was
to be able to make a unanimous decision with respect to class
membership. The minimum error rate using the average-class
approach was obtained at a threshold value of 2.42 and
involved a subset of only 25 genes, giving a further reduction
of 12 genes (Supplementary Fig. 2) (Additional file 4). Also, 10
(7 breast cancer and 3 non-breast-cancer samples) of the 60
samples were misclassified, which is a slightly better result
than that obtained with 37 genes, where there were 3 nonde-
cisions (Supplementary Fig. 3) (Additional file 5).
32 59 Benign tumor, fibroadenoma # 2 +
34 45 Benign density Type 2 diabetes 2 +
41 50 Fibrosis, benign Size histology 60 
mm
1+
43 51 Radial scar Size histology 10 
mm
1+
52 47 Benign density # 2 ND
54 52 Benign microcalcifications Cancer, large 
intestine, 1992
1+
58 46 Benign density # 2 +
Subgroup A3: Women with no reported breast abnormality
Sample ID Age (y) Comments Times assayed Prediction 
(37 genes)
64 2 #3 +
93 0 Breast feeding 2 +
10 34 Breast feeding 3 +
21 26 #1 +
22 - #1 +
18* 18 Week 1 2 +
23* Week 2 1 +
24* Week 3 1 +
26* Week 4 2 +
25* Week 5 1 +
33 34 Pregnant, 8 months 3 -
37 51 Acute bacterial 
infection in 
addition to chronic 
Epstein–Barr virus 
infection
1-
46 27 Pregnant, 6 months 1 -
47 29 Pregnant, 9 months 1 -
55 43 #1 +
56 43 #2 +
57 22 #2 +
Sample detail. Stage 0, in situ carcinoma; Stage I, invasive carcinoma with tumor size <20 mm; Stage II, invasive carcinoma with tumor size >20-50 
mm; Stage III, invasive carcinoma with tumor size >50 mm. Stage IV, cancer spread to distant parts. *, Blood samples taken on five consecutive 
weeks from the same woman; -, incorrectly predicted; #, no relevant information available; +, correctly predicted; DCIS, ductal carcinoma in situ; 
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; n.a., not available; ND, nondecision.
Table 1 (Continued)
Gene-expression patterns in 60 blood samples obtained from 56 different womenAvailable online http://breast-cancer-research.com/content/7/5/R634
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Table 3 shows the shrunken t-statistic scores of the selected
37 predictive genes for comparing breast-cancer class to non-
breast-cancer class, the genes in the public databases to
which they show sequence similarity, and their putative biolog-
ical function. The relative expression of 12 predictive genes
with highest scores is presented in Fig. 2. The majority of the
predictive genes (29 of 37) had a decreased expression (pos-
itive score) in the samples from breast cancer patients. The
identity of predictive genes was determined by partially
sequencing the corresponding spotted cDNA clones and
searching for gene similarities in public databases.
Sequence analysis revealed that 8 of 35 predictive genes con-
tained redundant information. Since the arrayed cDNAs were
derived from randomly picked clones from a library con-
structed from whole blood from 550 healthy individuals, we
had expected a redundancy of about 20% among the selected
genes. Of the 35 genes, 18 (51%) encoded ribosomal pro-
teins. In comparison, the frequency of cDNAs representing
ribosomal proteins was estimated to be only about 8% among
the arrayed cDNAs. All genes encoding ribosomal proteins
had reduced expression in samples from breast cancer
patients, indicating a decrease in ribosome production in the
blood cells of these patients. Also, genes encoding a transla-
tion elongation factor, eEF1 and RACK1 (receptor for
Table 2
Confusion matrix of prediction results using 37 genesa
True/Predicted C N Error rateb
C 17 6 0.26
N 4 30 0.12
aWhen there was no majority for either the breast-cancer or non-breast-cancer class, the prediction was regarded as a nondecision. bTotal error 
rate = 0.18; 3 nondecisions. C, breast-cancer samples; N, non-breast-cancer samples.
Figure 2
Relative expression of 13 predictive genes with the highest scores in breast-cancer and non-breast-cancer samples Relative expression of 13 predictive genes with the highest scores in breast-cancer and non-breast-cancer samples. Red circles represent samples 
from women with breast cancer and green circles represent samples from women with no signs of breast cancer. The number on the upper axis rep-
resents the position ID of predictive genes in the array (Table 3).Breast Cancer Research    Vol 7 No 5    Sharma et al.
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Table 3
Details of the identified 37 predictive genes
Accession no. Gene similarity Putative cellular function Position ID Scorea
BC000514 Ribosomal protein L13a Ribosome production 19AM 0.8377
BC007512 Ribosomal protein L18a Ribosome production 31AJ 0.7321
BC019093 Guanine nucleotide binding protein, beta polypeptide 
2-like; RACKs (receptors for activated C kinase)
Protein translation 12AM 0.6972
BC009696 Interferon induced transmembrane protein 2 Cell – environment interaction, 
Immune response
12Q -0.6962
BC047681 S100 calcium binding protein A9 (Calgranulin B) Defence; inhibition of casein kinase II 31J -0.6444
BC066901 H3 histone, family 3B (H3.3B) Chromatin remodelling 5AK -0.6394
BC034149 Ribosomal protein S3 Ribosome production 23V 0.639
AK026634 Highly similar to HUMTI227HC, mRNA for TI-227H - 21AH 0.627
BC047681 S100 calcium binding protein A9 (Calgranulin B) Defence; inhibition of casein kinase II 24AQ -0.627
BC001126 Ribosomal protein S14 Ribosome production 28T 0.6231
NM_000980 Ribosomal protein L18a Ribosome production 31AF 0.6215
AY495316 Cytochrome c oxidase subunit, COX 1 Mitochondrial electron transport chain 15AK 0.6112
NM_001016 Ribosomal protein S12 Ribosome production 22S 0.6102
- - - 20AG 0.5839
BC016378 Ribosomal protein S11 Ribosome production 8S 0.5827
AY495316 Cytochrome c oxidase subunit, COX 1 Mitochondrial electron transport chain 27AG 0.5729
AF077043 Ribosomal protein L36 Ribosome production 3AR 0.5699
AF346981 Mitochondrial 16S rRNA Ribosome production 25P 0.5507
BC013857 H3 histone, family 3A Chromatin remodelling 3T -0.5496
M22146 Ribosomal protein S4 Ribosome production 31U 0.5176
BC016857 Ferritin, heavy polypeptide 1 Iron storage; defence against ROS 6N -0.5134
BC053370 Ribosomal protein SA Ribosome production 2G 0.5113
BC010165 Ribosomal protein S2 Ribosome production 2V 0.5071
BC009689 Cyclin D-type binding protein E2F-mediated transcription 21O 0.4978
BC018641 Eukaryotic translation elongation factor 1α  (eEF1A) Protein translation 4AA 0.4974
D87735 Ribosomal protein L14 Ribosome production 19H 0.486
- - - 6AQ 0.4837
BC016857 Ferritin, heavy polypeptide 1 Iron storage; defence against ROS 3AB -0.481
BC012146 Ribosomal protein L3 Ribosome production 32AM 0.4776Available online http://breast-cancer-research.com/content/7/5/R634
R642
activated C kinase), were expressed at a lower level in sam-
ples from cancer patients, indicating reduced protein transla-
tion activity in these samples. RACK1 plays a key role in the
joining of 60S and 40S subunits into a functionally active 80S
ribosome complex [13].
Among the eight predictive genes with increased expression
in samples from breast cancer patients, two encoded histone
replacement protein H3.3, which is thought to be involved in
chromatin remodelling [14], and six encoded proteins that may
play a role in defense-related functions. Four genes with
increased expression encoded ferritin and calgranulin B. Ferri-
tin is involved in intracellular storage and sequestration of iron.
Increased expression of ferritin has been shown to reduce the
accumulation of reactive oxygen species in response to oxi-
dant challenge in HeLa cells [15]. Calgranulin B is expressed
by blood cells both during infection and during inflammation
and may play a role in host defense [16]. Interferon-induced
transmembrane protein 2 has been implicated in the immune
response, while human granule proteoglycan peptide core is
assumed to form stable complexes with proteases and other
granule-localized proteins to prevent their intragranular autoly-
sis and facilitate their concerted action extracellularly [17].
Interestingly, most predictive genes identified in this study
belonged to the family of genes that exhibited altered expres-
sion in neutrophils after stimulation by nonvirulent and virulent
bacterial stimuli [18,19].
Discussion
This is a first report demonstrating that breast cancer affects
gene-expression patterns in peripheral blood cells during early
stages of disease development. The results presented repre-
sent an initial phase in the development of a blood-based
gene-expression test for breast cancer detection. A larger
number of samples, from both women with and women
without the disease, should be further analyzed before the clin-
ical efficacy of our finding can be evaluated. However, the
results clearly show that by analyzing the expression pattern of
selected genes in blood cells, a diagnostic test for breast can-
cer detection can be efficiently developed.
In the present study, we examined gene-expression patterns in
peripheral blood cells as a whole, rather than specific cellular
subsets. It has recently been shown that individual variations
in gene-expression pattern in peripheral blood could be traced
to altered relative proportions of the specific blood cell sub-
sets [9]. If there were systematic differences in the relative pro-
portions of peripheral blood cell types in women with breast
cancer and those without this disease, such differences might
explain the observed gene-expression patterns. Interestingly,
Whitney and colleagues [9] found that transcripts involved in
protein synthesis were over-represented in lymphocytes and
monocytes as compared with granulocytes. The reduced
expression of transcripts involved in protein synthesis and the
increased expression of transcripts involved in defense
responses in breast cancer patients may reflect a systematic
shift in favor of granulocytes as compared with lymphoid cells
in the peripheral blood of breast cancer patients. However, to
our knowledge, no such systematic shift during breast cancer
development has been reported, and the subject requires fur-
ther investigation. Alternatively, changes in the expression pat-
tern of genes involved in protein synthesis, chromatin
remodelling, and defense-related genes in the blood samples
of breast cancer patients may indicate systematic activation of
certain blood cell subsets such as neutrophils in these
patients.
Our ability to correctly assign the class of samples from
women with Crohn's disease, rheumatic disease, or diabetes
as non-breast-cancer suggests that breast cancer affects the
expression pattern of identified predictive genes differently
from some of the diseases associated with anemia and
chronic inflammation. The correct prediction of two samples
from a woman with ductal carcinoma in situ further suggested
BC001126 Ribosomal protein S14 Ribosome production 25R 0.4759
BC006784 Ribosomal protein S14 Ribosome production 24AJ 0.4695
J03223 Human secretory granule proteoglycan peptide core Defence (may neutralize hydrolytic 
enzymes)
11H -0.4681
AY147037 Myeloid/lymphoid or mixed-lineage leukemia 5 cDNA Chromatin remodeling and cellular 
growth suppression
30AP 0.4669
CD246392, EST Agencourt_14095501 NIH_MGC_172 cDNA - 8AK 0.4666
AY339570 Cytochrome c oxidase subunit, COX 1 Mitochondrial electron transport chain 2E 0.4662
U43701 Human ribosomal protein L23a Ribosome production 8G 0.4629
AY495252 Mitochondrial 16S rRNA Ribosome production 8AF 0.4625
The position of genes in the array is shown as well as their scores, the accession number of sequences in public databases that match them, and 
their known or putative cellular function. aThe score is a shrunken t-statistic for comparing breast-cancer class to non-breast-cancer class. A positive 
score means that expression was greater in the noncancer sample than the cancer sample; a negative score means that expression was greater in 
the cancer sample than the noncancer sample. -, no information available; ROS, reactive oxygen species.
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that malignant lesions, though confined within the breast duct,
may induce similar changes in the expression pattern of these
genes to the changes seen during the more advanced stages
of breast cancer (stages I to III). However, incorrect prediction
of a sample obtained from a woman with invasive lobular car-
cinoma and tubular adenocarcinoma and from a woman where
the cancer had spread to supraclavicular and infraclavicular
nodes indicates that malignancy in itself is not a prerequisite
condition for the observed changes in the expression pattern
of the identified predictive genes.
The efficient prediction of samples derived from patients
whose cancer had not yet spread to lymph nodes shows that
a blood-based gene-expression test can be developed for
breast cancer detection in asymptomatic patients. As com-
pared with existing methods, an accurate method for breast
cancer detection based on peripheral blood as a clinical sam-
ple will be highly desirable because of the easy accessibility
and the less invasive procedure for obtaining samples. The
test could be integrated as an adjunct to already established
methods and be used to improve their efficacy. For example, a
blood-based gene-expression test could assist mammography
in discriminating between benign and malignant breast abnor-
malities. It could become a part of routine screening programs,
especially when the patient has an increased risk for breast
cancer.
It is important that any test intended for use in breast cancer
diagnosis has a low rate of both false positives and false neg-
atives. Based on the expression pattern of identified 37 genes,
the prediction achieved corresponded to a false positive rate
of 0.12 and false negative rate of 0.26. Since, the main goal of
this work was to see whether the information about breast can-
cer is present in peripheral blood samples in the form of
changed gene-expression patterns, we analyzed only a limited
number of gene candidates in this study. The genes analyzed
corresponded to clones that were randomly picked from a
plasmid library constructed from whole blood of 550 individu-
als. The motivation for this approach for selecting gene candi-
dates was based on the assumption that if the expression
pattern of certain genes in blood cells is affected during early
stages of breast cancer, the genes affected would most likely
include ones involved in cell maintenance and general metab-
olism. Since such genes are expressed at high level in a cell,
they would be frequently represented in a cDNA library and
selected preferentially when randomly picked. It is our view
that expression techniques such as microarrays, where the
expression of thousands of genes can be monitored simulta-
neously, can further be used to screen for better predictive
genes and develop more accurate diagnostic models.
We envisage blood-based gene-expression tests to have the
potential of becoming a versatile and powerful tool for detec-
tion of disease, including other forms of cancers. As with
breast cancer, other diseases may also cause characteristic
changes in the biochemical environment of blood and affect
the gene-expression patterns in blood cells. Specific gene-
expression-based models can then be developed and used for
diagnostic purposes.
Conclusion
The results presented show that breast cancer even during
early stages of disease development affects the expression
pattern of certain genes in peripheral blood cells. By identify-
ing these genes and analyzing their expression pattern, it is
possible to develop a blood-based gene-expression test for
early detection of breast cancer. Additional studies with a
large sample size, both from women with and without the dis-
ease, are warranted to confirm or refute this finding.
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